Pre-Rheumatoid Arthritis: Can We Define It and Prevent Its Progression?

Pre-Rheumatoid Arthritis: Can We Define It and Prevent Its Progression? is organized by Cleveland Clinic Center for Continuing Education.

Release Date: July 12, 2017
Expiration Date: July 12, 2019

Target Audience:
The online series is designed for rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders.

Accreditation:
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Description :
Biologic Therapies VII: Precision Medicine in the Biologic Era online series brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.

This webcast reviews RA-related biomarkers in patients prior to the first development of clinically apparent arthritis. The role of the mucosal immune system in the initial development of antibodies to citrullinated protein/peptide antigens will be explained. The evolving science in preclinical RA and management of high risk individuals for future RA will also be discussed.

Learning Objectives :
• Describe the evolution and timing of appearance of RA-related biomarkers in the seropositive disease subset of patients prior to the first development of clinically apparent arthritis.
• Explain the postulated role of the mucosal immune system in the initial development of antibodies to citrullinated protein/peptide antigens (ACPA).
• Devise a new therapeutic and diagnostic paradigm that incorporates the evolving science in preclinical RA and will drive the management of individuals who are at high risk for future RA.

Additional details will be posted as soon as they are available.